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Abstract
Background: Paraoxonase-1 (PON1) is an antioxidant enzyme that attenuates the production of the monocyte
chemoattractant protein-1 (MCP-1) in vitro. Although oxidation and inflammation are closely related processes, the
association between PON1 and MCP-1 has not been completely characterised due, probably, to that the current
use of synthetic substrates for PON1 measurement limits the interpretation of the data. In the present study, we
explored the relationships between the circulating levels of PON1 and MCP-1 in human immunodeficiency virus-
infected patients in relation to the multifunctional capabilities of PON1.
Methods: We measured selected variables in 227 patients and in a control group of 409 participants. Serum PON1
esterase and lactonase activities were measured as the rates of hydrolysis of paraoxon and of 5-(thiobutyl)-
butyrolactone, respectively. Oxidised LDL and MCP-1 concentrations were determined by enzyme-linked
immunosorbent assay. High-density lipoproteins cholesterol, apolipoprotein A-I, and C-reactive protein
concentrations were measured by standard automated methods.
Results: There were significant relationships between PON1 activity and several indices of oxidation and
inflammation in control subjects and in infected patients. However, these relationships varied not only with disease
status but also on the type of substrate used for PON1 measurement.
Conclusion: The present study is a cautionary tale highlighting that results of clinical studies on PON1 may vary
depending on the methods used as well as the disease studied. Until more specific methods using physiologically-
akin substrates are developed for PON1 measurement, we suggest the simultaneous employment of at least two
different substrates in order to improve the reliability of the results obtained.
Background
Paraoxonase-1 (PON1) is an enzyme with esterase and
lactonase activities found in the circulation bound to
high-density lipoproteins (HDL). Research into PON1
has increased exponentially over the past few years
because many studies associate this enzyme with inflam-
mation and cardiovascular disease. The physiological
substrates of PON1 have not been completely delineated,
but in vitro studies suggest that a key function is to
degrade oxidised phospholipids in low-density lipopro-
teins (LDL) and HDL and, as such, has an antioxidant
role [1]. PON1 attenuates the production of the mono-
cyte chemoattractant protein-1 (MCP-1) in cultured
endothelial cells. MCP-1 is a pro-inflammatory chemo-
kine involved in the initial steps in the formation of the
atheromatous plaque [2]. Previous studies from our
group have shown that HIV-infected patients have
decreased serum PON1 activities and increased plasma
MCP-1 concentrations, and that certain genetic poly-
morphisms of both molecules are associated with the
presence of sub-clinical atherosclerosis [3-5]. Although
oxidation and inflammation are closely related processes,
the association between PON1 and MCP-1 has not been
completely characterised. This is probably due, at least in
part, to the limitations of the current methods of
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synthetic substrates limits the interpretation of the data
since it is not clear to what extent these measured activ-
ities reflect the real endogenous physiological activity of
the enzyme.
The present study was aimed at extending our obser-
vations on the relationships between the circulating
levels of PON1 and MCP-1 in HIV-infected patients.
Using two assay methods for the different enzyme activ-
ities (esterase and lactonase), we sought to evaluate pos-
sible discrepancies relating to the analytical methods
(different substrates) employed.
Methods
Subjects
We studied 227 HIV-infected patients and 409 healthy
volunteers. The exclusion criteria for the patients were
age ≤ 18 years, and having an AIDS-related disease. The
clinical characteristics of these patients have been pre-
viously published [3]. The study was approved by the
Ethics Committee of Hospital Universitari de Sant Joan
de Reus (Catalonia).
Biochemical analyses
Serum PON1 esterase activity was measured as the
hydrolysis of the substrate paraoxon [6], and the lacto-
nase activity was measured as the hydrolysis of the
substrate 5-(thiobutyl)-butyrolactone (TBBL) [7]. HDL-
cholesterol and apolipoprotein A-I were analysed by
standard methods (Beckman-Coulter, Fullerton, CA,
U S A ) ,o x i d i s e dL D La n dM C P - 1b ye n z y m e - l i n k e d
immunosorbent assay (Mercodia, Uppsala, Sweden, and
Prepotech, London, UK, respectively), and C-reactive
protein (CRP) by a high sensitivity immunoturbidimetric
method (Beckman-Coulter).
Statistical analysis
Normality of distributions was tested with the Kolmo-
gorov-Smirnov test. We used Spearman’s( r) test to iden-
tify correlations between variables, and curve estimation
analyses when non-linear correlations were found. Statis-
tical analyses were performed with the SPSS 17.0 statisti-
cal package. Results are presented as means (SD).
Results
Results of the selected biochemical variables are sum-
marised in Table 1. There were significant decreases in
serum PON1 activity and HDL-cholesterol and apolipo-
protein A-I concentrations in HIV-infected patients with
respect to the control group. Conversely, there were sig-
nificant increases in plasma MCP-1 and serum CRP
concentrations. Oxidised LDL levels showed a slight
trend towards an increase, but differences did not reach
statistical significance. We observed a significant inverse
relationship between serum PON1 esterase activity and
oxidised LDL levels in the control subjects (linear; r =
-0.125; p = 0.046), but not in the HIV-infected patients
(Figure 1A). Conversely, we observed a significant curvi-
linear relationship between PON1 esterase activity and
MCP-1 in HIV-infected patients (p = 0.023), but not in
the control group (Figure 1B). Esterase activity was also
significantly correlated with HDL-cholesterol concentra-
tion in control subjects (linear; r = 0.217; p < 0.001)
and in HIV-infected patients (curvilinear; p = 0.004).
We did not find any statistically significant relationship
between serum PON1 esterase activity and apolipopro-
tein A-I or CRP in the patient or control subject groups.
We observed a significant curvilinear relationship
between serum PON1 lactonase activity and oxidised
LDL (p = 0.003) in HIV-infected patients (Figure 1C),
but not in the control group. Conversely, lactonase
activity was significantly related to MCP-1 in the control
subjects (linear; r = 0.208; p = 0.002) but not in HIV-
infected patients (Figure 1D). We also found significant
associations between serum PON1 lactonase activity and
apolipoprotein A-I (linear; r = 0.281; p < 0.001) and
CRP (curvilinear; p = 0.027) in HIV-infected patients,
but not in the control group.
Discussion
The present study presents a puzzling picture in that the
observed relationships between PON1 activity and several
indices of oxidation and inflammation depended not only
on the HIV infection but also on the substrate used to
measure PON1. Methods using the non-physiological
paraoxon as substrate have traditionally been used to mea-
sure PON1 activities, the levels of which have been pro-
posed as indicators in the prediction of cardiovascular
disease [1]. Recently, the lactonase activity assay using
TBBL has been developed and evaluated [7,8] and,
although TBBL is also a synthetic substrate, it probably
measures an activity that is closer to the physiological
state, since it represents a chemical reaction that is lac-
tone-degrading and, as such, is probably closer to the phy-
siological basis of PON1 activity. Experimental evidence
suggests that, essentially, the lactonase assay measures
Table 1 Results of the biochemical measurements
Parameter Control
subjects
HIV-infected
patients
p -value
PON1 esterase activity, U/L 410.7 (132.5) 336.8 (115.4) < 0.001
PON1 lactonase activity, U/L 6.8 (3.0) 5.3 (1.6) < 0.001
HDL-cholesterol, mmol/L 1.50 (0.01) 1.17 (0.03) < 0.001
Apolipoprotein A-I, g/L 1.69 (0.03) 1.38 (0.31) < 0.001
Oxidised LDL, U/L 85.7 (80.1) 94.0 (90.8) NS
MCP-1, ng/L 61.54 (1.97) 71.57 (2.80) 0.003
C-reactive protein, mg/L 0.75 (0.01) 4.13 (3.30) < 0.001
Results are shown as means and SD (in parenthesis)
Parra et al. Lipids in Health and Disease 2010, 9:32
http://www.lipidworld.com/content/9/1/32
Page 2 of 4PON1 that is tightly bound to HDL particles, while the
esterase assay measures the tightly as well as the loosely
bound enzyme [7]. The differences between methods,
therefore, could also be related to the observed changes in
structure and composition of the HDL particles during
HIV infection. These changes may be due to the chronic
inflammation per se, or to secondary effects of the antire-
troviral treatments [9]. There is the possibility that these
changes affect PON1 activity and that this is further influ-
enced by the type of substrate used to measure PON1. We
acknowledge that the different relationships observed
between PON1 activities and MCP-1 in HIV-infected
patients may, possibly, not be extrapolated to non-diseased
control subjects. Nevertheless, the wide distribution of
PON1 in different cell types and co-localisation with
MCP-1 in most tissues [10] suggests a fundamental asso-
ciation between these two molecules in the regulation of
oxidation and inflammation.
Conclusions
We conclude with a cautionary note to researchers con-
ducting clinical studies on PON1; the experimental
Figure 1 Relationships between serum PON1 esterase and lactonase activities and oxidised LDL and MCP-1 concentrations in the
control group (open circles) and HIV-infected patients (closed circles). The lines within the graphs represent the linear or curvilinear
regression lines of the distributions of measured values in the control group (dashed lines) and the HIV-infected patients (continuous lines).
NS = not significant.
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the methods of measurement used, and the disease stu-
died. Until more specific methods using physiologically-
akin substrates are developed for PON1 measurement,
the simultaneous employment of at least two different
substrates to measure PON1 activity would be the
recommended so that the reliability of the results may
be improved.
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